Coherus Queries Higher Dose Aflibercept Amid Biosimilar Eylea Deal

Potential For More Ophthalmology Products With ‘Additional Bandwidth’

 
• By Dean Rudge

Coherus BioSciences is feeling bullish about its potential in the biosimilar ophthalmology space after agreeing to bring on board a biosimilar Eylea (aflibercept) candidate, with an eye on launching potentially in 2025.

question mark on a woman's hand. - Image
The anti-VEGF market is worth more than $7bn, Coherus says • Source: Shutterstock

More from Biosimilars

More from Products